In the necitumumab plus gemcitabine and cisplatin group , the number of patients with at least one grade @ or worse adverse event was higher ( @ -LSB- @ % -RSB- of @ patients ) than in the gemcitabine and cisplatin group ( @ -LSB- @ % -RSB- of @ ) , as was the incidence of serious adverse events ( @ -LSB- @ % -RSB- of @ patients vs @ -LSB- @ % -RSB- of @ ) .